Bridgewater, NJ (November 1, 2019) – Cosette Pharmaceuticals, Inc., a generic pharmaceutical company primarily focused on extended topical and suppository products, announced today that it will be commercializing Migergot® (ergotamine tartrate and caffeine suppositories) for the US market and will continue its role as the manufacturer.
“We are very pleased to be launching Migergot® for several important reasons,” said Walt Kaczmarek, President and Chief Executive Officer of Cosette. “First, it marks an important milestone as the first product in our portfolio to be marketed in a Cosette label to customers and patients. Second, it demonstrates our continued commitment to enhancing the Cosette product line with products where we can leverage our expertise in suppositories and other differentiated dosage forms.”
Migergot® is indicated as a therapy to abort or prevent vascular headache such as migraine and migraine variants. To learn more about Migergot® please visit migergot.com or to place an order, please call 800-922-1038.
About Cosette Pharmaceuticals, Inc.
Cosette Pharmaceuticals, Inc. is a generic pharmaceutical company specializing in the areas of dermatology and allergy, with products available in dosage forms such as creams, ointments, lotions, solutions, gels, pastes and suppositories. The company was formed when Avista Capital Partners, a leading private equity firm focused on growth-oriented healthcare businesses, purchased the extended topicals and dermatology portfolio of G&W Laboratories in December 2018. Cosette is expanding its product offering by bringing new products to market via internal development and external licensing or acquisitions. For further information on Cosette Pharma, please visit the company’s website: cosettepharma.com.